Business Wire

Dr. Jack Kolenda from Toronto and Lux Vitae Worldwide Announce That The Steriwave Nasal Decolonization Treatment Has Been Successfully Used By The Rock Band KISS Since September of 2021, To Prevent The Transmission And Spread of Covid 19


Dr. Jack Kolenda from Toronto and Lux Vitae Worldwide Are Pleased To Announce That The Steriwave Nasal Decolonization Treatment, Has Been Successfully Used By The Rock Band KISS Since September of 2021, To Prevent The Transmission And Spread of Covid 19 on Their World Tour and In Treatment of Covid 19 Positive Individuals In Toronto and Throughout Canada.

Doc McGhee, the legendary manager of KISS says, "It would be impossible, not improbable, but impossible, for KISS to continue on its world tour without the protection of the Steriwave treatment."



Location: Vantage Venues, Conference Room S1, The Sun Life Tower, 150 King Street West, 27th Floor, Toronto ( when you arrive at the 27th Floor, please see reception and advise them that you are attending the Lux Vitae press conference)

For Press Conference Details and to confirm attendance please call:

(416) 912-7130









At a time when many sports teams and entertainers were isolating themselves due to the threat of COVID-19, in August of 2021 the rock band, KISS, embarked on the largest rock and roll music tour since the beginning of the Coronavirus pandemic with a planned tour through 61 cities in 31 countries on four continents of the world. On their date in Philadelphia on August 26, 2021 Paul Stanley the co founder, lead vocalist and lead guitarist of KISS contracted the Covid 19 infection and KISS had to cancel 9 concert dates at the beginning of their world tour. The legendary manager of KISS, Doc McGhee, had heard about the Steriwave nasal decolonization treatment and after substantial due diligence, made the decision to deploy the Steriwave treatment on the KISS world tour.

Under the oversight of Dr. Jack Kolenda, an ENT surgeon and the medical director of the Verso Surgery Centre in Oakville, Ontario, Canada, and Lux Vitae Worldwide, Doc McGhee, manager of KISS, deployed the Steriwave nasal decolonization treatment to protect the KISS band, management and crew during its world tour, to prevent the transmission and spread of Covid 19. The treatment protocol required KISS and its management and crew to treat themselves with the Steriwave treatment for four minutes every show day, which is the exact same treatment protocol that has been used at Vancouver General Hospital, as the standard of care for more than 12 years, to treat almost all patients prior to surgery, to protect against the spread of MRSA and other hospital acquired infections.

The Steriwave COVID-19 protocol, perfected during the pandemic by Dr. Jack Kolenda, was used to treat 344 patients Covid 19 positive individuals with the Steriwave treatment, to reduce the systemic progression of symptoms of Covid 19 and to promote more rapid healing. Several of these patients, will be present at the press conference to report on their personal experiences with the Steriwave treatment.

Dr. Kolenda had been utilizing the Steriwave nasal decolonization treatment for the same purpose it has been used for at Vancouver General Hospital, to prevent his patients from contracting surgical site infections after surgery. At the onset of the Covid 19 pandemic, in the absence of any preventive measures for the prevention of transmission and spread of Covid 19 and the absence of any treatments for Covid 19 positive individuals, Dr. Kolenda reviewed existing literature and observed that patients with lower viral and bacterial loads in the nose were less likely to die or be hospitalized. With this information, Dr. Kolenda initiated the use of the Steriwave for treatment for his staff and patients to prevent the transmission and spread of Covid 19. The adoption of the Steriwave treatment in his surgery centre had a protective effect against Covid 19 infections among his staff, thereby encouraging Dr. Kolenda to expand the use of the Steriwave treatment to create a treatment protocol, The Kolenda Argemi protocol, which informed successful clinical trials at Sunnybrook Hospital (Toronto) and the Clinica University of Navarra, a world leading medical and research institute in Pamplona, Spain. Both of these trials subsequently demonstrated substantial reduction of viral load in the anterior nares (the front of the nose) and reduction of Covid 19 infectivity in Covid 19 positive patients.

The Steriwave nasal photodisinfection treatment is a non-antibiotic, light-based, antimicrobial therapy developed by Vancouver based Ondine Biomedical. Steriwave is able to quickly eradicate all variants of the Coronavirus and any infective bacterial or fungal co-factors in minutes. The Steriwave Covid 19 treatment protocol developed by Dr. Kolenda and Dr. Josep Maria Argemi, is a topical noninvasive, antiviral, upper respiratory tract treatment, that kills the coronavirus in the anterior nares, a primary source of infection. In 2021, the Steriwave treatment received international recognition by the International Conference of Prevention and Infection Control (ICPIC), Geneva as an Innovation Excellence Award winner for the use of the Steriwave treatment, in the treatment of Covid 19 positive individuals.

Dr. Kolenda was the first doctor in the world to provide the Steriwave treatment to Covid 19 positive patients, some of whom were immunocompromised, and highly symptomatic, observing rapid resolution of Covid 19 symptoms in all of the individuals treated with the Steriwave treatment. Highly importantly, none of the Covid 19 positive patients treated with the Steriwave treatment were admitted to hospital. There was recent confirmation of the efficacy of the Steriwave, Kolenda Argemi treatment protocol in a randomized control trial study of COVID-19 patients which was carried out by the Clinica Universidad de Navarra in Pamplona, Spain and published in Frontiers in Cellular and Infection Microbiology ( The University of Navarra randomized control trial demonstrated that the Steriwave treatment was able to substantially reduce viral load in the anterior nares (front of the nose), substantially reducing Covid 19 infectivity as well as rapidly resolving COVID symptoms.

Lead author, co-principal investigator, and Associate Professor at the Department of Occupational Medicine at the University of Navarra, Dr Alejandro Fernandez-Montero commented, "This randomized, controlled study shows that photodisinfection could be an effective and safe novel treatment for SARS-CoV-2 carriers, significantly decreasing the infectivity period. Most exciting is the demonstration of an adaptive immune response in treated patients. This is the basis of vaccination, and it means that nasal decolonization might provide an alternative, low-cost, widely accessible, respiratory virus treatment during future pandemics. The treatment specifically helped to maintain, over time, the cell-mediated immunity, which is remarkable as this is the immune protection needed against severe disease."

Dr. José Luis Del Pozo, Head of Infectious Diseases Division and Clinical Microbiology at the Clínica Universidad de Navarra, Co-Principal Investigator, and Study Author, commented "This study expanded our understanding of SARS-CoV-2 pathogenesis, because interestingly, we showed that treatment with aPDT applied only to the nasal passages also reduced SARS-CoV-2 colonization of the nasopharyngeal region. This implies that we might be able to slow viral spread from the upper to the lower respiratory tract, reducing the extent of illness and thereby reducing pressure on hospital facilities such as the ICU. It also means that we might be able to slow or inhibit viral spread from person to person during an outbreak, in both clinical and non-clinical settings, even when those patients have been previously vaccinated."

A significant finding of the randomized control trial is that Steriwave photodisinfection substantially prolonged patient immunity against Covid 19 at 20 weeks after treatment. This finding suggests that the Steriwave treatment is one of the most important innovations in the fight against coronaviruses and other respiratory pathogens. The Steriwave treatment has been proven to be safe and effective for both prevention of the transmission and spread of Covid 19 and treatment of COVID-19 positive patients and is a highly effective solution to protect front line workers and health professionals as part of PPE.

In a recent press release commenting on the University of Navarra, Steriwave randomized control trial results, Ondine Biomedical founder and CEO, Carolyn Cross, stated " The Clínica Universidad de Navarra study sheds new light on the Steriwave treatment of respiratory viruses, where antibiotics are entirely ineffective and new anti-viral therapies are limited. As new Covid 19 variants rapidly emerge across the globe, we look forward to being able to play our part in helping our communities, hospitals, clinics, and emergency workers deal with these new threats. Steriwave has been successfully used in Canadian hospital surgical suites for more than ten years, significantly reducing post-surgical infection rates, length of stay and hospital readmission rates. Eliminating a broad spectrum of pathogens from the nose prior to surgery has proven to be a major factor in reducing hospital-acquired infections in these hospitals. More than 100,000 patients have already benefited from this painless, rapid approach to infection control – all without the fear of resistance formation and the possibility of antibiotic adverse effects."

The Steriwave nasal photodisinfection decolonization treatment was developed and is produced by Ondine Biomedical, a Vancouver-based life sciences company (, which trades on the London AIM Stock Exchange under the trading symbol (OBI). Ondine Biomedical is the world leader in developing and creating antimicrobial photodisinfection treatments and technologies with 7 products in its pipeline.

The Steriwave antimicrobial photodynamic therapy treatment and technology eradicate and mitigate, what the WHO, CDC and the Bill and Melinda Gates Foundation identify as one of the greatest threats to humanity in the next decade; antibiotic resistant infection and antimicrobial resistance (AMR).

The Steriwave treatment is approved in Canada, The European Union, The United Kingdom, Ireland, Australia and Mexico.

The Steriwave treatment is not for sale or distribution in the United States.

To view this piece of content from, please give your consent at the top of this page.

Contact information

(416) 912-7130

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Abbove Awarded as Best Wealth Technology Outsourcing Solution in Europe30.3.2023 21:00:00 CEST | Press release

Abbove, the wealth planning technology platform was awarded as ‘best technology Outsourcing solution’ at WealthBriefing European Awards 2023. This news coincides with the milestone of 1000 wealth advisors using the platform to guide 30,000 families in achieving their wealth goals. The WealthBriefing Awards have been designed to recognize outstanding organizations grouped by specialism and geography, which the panel of independent judges deemed to have ‘demonstrated innovation and excellence during the last year’. The Belgian wealth-tech is not stopping there, as it now has over 1,000 wealth advisors from private banks and family offices using its technology to place holistic wealth advice at the center of their client relationship. Banking groups such as BNP Paribas Fortis, Quintet Bank or Deutsche Bank in Belgium are trusting Abbove to improve the way they manage, collect and process their client wealth data. Commenting on the firm’s triumph, Guillaume Desclée, CEO, Abbove said: "It’s

Verimatrix Gains EMVCo Security Evaluation Certificate as Software Protection Tool for Mobile Payment Apps30.3.2023 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that its Verimatrix XTD Code Shield toolkit for Android mobile applications received an EMVCo Security Evaluation Certificate as a Software Protection Tool (SPT). The designation demonstrates that Verimatrix’s technology mobile app security tool meets stringent payment security requirements. EMVCo is the global technical body that facilitates the worldwide interoperability and acceptance of secure payment transactions by managing and evolving the EMV® Specifications and related testing processes. Verimatrix gained the Security Evaluation Certificate following the completion of a robust evaluation by Riscure, a leading mobile security lab accredited by EMVCo. As one of Verimatrix’s latest efforts to further streamline the go-to-market process for Android app customers, the EMVCo Security Evaluation Certificate stands as a likely

H.I.G. Capital Acquires Synecore Limited and Meesons Futures Limited to Create the Andwis Group30.3.2023 17:03:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative asset investment firm with $55 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Synecore Limited (“Synecore”) and Meesons Futures Limited (“Meesons”). Synecore and Meesons will join forces with H.I.G.’s existing portfolio companies, CPS and Classic Lifts, to form the Andwis Group (the “Andwis” or the “Andwis Group”), a family of best-in-class technical services providers. The financial terms of the transactions have not been disclosed. Synecore specialises in the delivery and maintenance of HVAC, electrical, air conditioning, and refrigeration services to the hospitality, retail, leisure, and commercial sectors. Synecore, and its network of engineers and suppliers, provides both maintenance and installation services, often supporting site rollout and refurbishment programs. Founded in 1864, Meesons is a physical security and entrance control solutions provider for both crit

EMIT IMAGING Announces Appointment of Dr. Matthew Silva as Chief Executive Officer30.3.2023 16:10:00 CEST | Press release

EMIT IMAGING, Inc. (“EMIT” or the “Company”) is pleased to announce the appointment of Dr. Matthew Silva as the company's new Chief Executive Officer. EMIT IMAGINGis the world leader in Cryo-Fluorescence Tomography (CFT) imaging, an innovative imaging technology used by pharmaceutical, biotechnology, and academic researchers worldwide. EMIT’s imaging platform, XerraTM, is a state-of-the-art technology that provides high-sensitivity and high-resolution 3D fluorescence images of biological samples. Dr. Silva brings diverse experience and expertise in both science and business to the role, specifically drawing on technical training in biomedical engineering and previous executive positions in pharma and scientific services. Recently, Dr. Silva served as CEO of Invicro, LLC, an imaging contract research organization and subsidiary of REALM IDx/Konica Minolta. "We are thrilled to have Dr. Silva join the EMIT team," said Dr. Jack Hoppin, EMIT’sfounder and Chairman of the Board. "Matt has the

Stilla Technologies and Atila BioSystems to Co-Develop High-Plex Digital PCR Kits for Oncology30.3.2023 15:11:00 CEST | Press release

Stilla Technologies and Atila BioSystems today announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system (Stilla Technologies). The digital PCR kits, optimized specifically for use with the 6-color naica® system, will be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples taken from patients with high-occurring cancer indications such as breast, lung, melanoma, prostate, and colorectal cancers. The co-labeled digital PCR kits will be promoted globally by Atila and Stilla and will be designed For Research Use Only (RUO) applications. “We are witnessing the continued promise, utility, and proliferation of digital PCR in the analysis of liquid biopsies for use in therapeutic development and in patient diagnosis and monitoring of oncological disease,” says Philippe Mourère, President and CEO of Stilla Technologies. “Co-developing products with a strong assay partner in Atila will allow highly st